|
| 37935879 | Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2024 |
| 38008690 | Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy. | Clin Genitourin Cancer | 2024 |
| 36179990 | External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. | Int J Radiat Oncol Biol Phys | 2023 |
| 37714961 | Relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy. | Prostate Cancer Prostatic Dis | 2023 |
| 37803241 | Impact of persistent PSA after salvage radical prostatectomy: a multicenter study. | Prostate Cancer Prostatic Dis | 2023 |
| 37704503 | Recurrent Gleason Score 6 Prostate Cancer After Radiotherapy or Ablation: Should We Observe Them All? Results from a Large Multicenter Salvage Radical Prostatectomy Consortium. | Eur Urol Focus | 2023 |
| 37979953 | Identification of amyloidosis of the urinary tract and prostate: Opportunities for early diagnosis & intervention in systemic disease. | Hum Pathol | 2023 |
| 37977513 | Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. | Hum Pathol | 2023 |
| 37676710 | Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. | Cancer Discov | 2023 |
| 35700531 | Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical Cystectomy. | Arch Pathol Lab Med | 2023 |
| 37192276 | Reply by Authors. | J Urol | 2023 |
| 37060201 | A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. | Cancer | 2023 |
| 37079876 | Vesicourethral Anastomotic Stenosis Following Radical Prostatectomy: Risk Factors, Natural History, and Treatment Outcomes. | J Urol | 2023 |
| 37370733 | Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy. | Cancers (Basel) | 2023 |
| 36698089 | Addressing the need for more therapeutic options in neuroendocrine prostate cancer. | Expert Rev Anticancer Ther | 2023 |
| 36652397 | Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference? | J Urol | 2023 |
| 36445045 | Intraoperative Blood Transfusion Is Associated With Increased Risk of Venous Thromboembolism After Radical Cystectomy. | J Urol | 2023 |
| 36682962 | Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary Cohort. | Eur Urol Focus | 2023 |
| 36906183 | Mass spectrometry-based assessment of prostate cancer-associated crystalloids reveals enrichment for growth and differentiation factor 15. | Hum Pathol | 2023 |
| 33303244 | Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. | Eur Urol | 2022 |
| 35843864 | Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers. | Eur Urol Focus | 2022 |
| 35638091 | Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. | Eur Urol Open Sci | 2022 |
| 35488914 | Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy. | World J Urol | 2022 |
| 35715319 | Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. | Eur Urol Oncol | 2022 |
| 36569505 | Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer. | BJUI Compass | 2022 |
| 36601046 | Effect of Preoperative Multiparametric Magnetic Resonance Imaging on Oncologic and Functional Outcomes Following Radical Prostatectomy. | Eur Urol Open Sci | 2022 |
| 36149448 | Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database. | World J Urol | 2022 |
| 36349914 | Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. | J Urol | 2022 |
| 36089822 | Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. | Prostate | 2022 |
| 36217395 | Ki-67, topoisomerase IIα and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort. | Transl Androl Urol | 2022 |
| 36082540 | Editorial Comment. | J Urol | 2022 |
| 33867307 | Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. | Eur Urol Focus | 2022 |
| 34981952 | Long-Term Risk of Clinical Progression Utilizing Magnetic Resonance Imaging Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence following Radical Prostatectomy. | J Urol | 2022 |
| 35094523 | Reply by Authors. | J Urol | 2022 |
| 35216892 | Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? | Urol Oncol | 2022 |
| 34905946 | Editorial Comment. | J Urol | 2022 |
| 35142865 | Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. | World J Urol | 2022 |
| 35236621 | Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists. | Urol Oncol | 2022 |
| 35108506 | Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer. | Cell Chem Biol | 2022 |
| 35082164 | Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. | Mol Cancer Res | 2022 |
| 35050303 | Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. | JAMA Oncol | 2022 |
| 34547921 | Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy. | J Urol | 2022 |
| 34694143 | Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. | J Urol | 2022 |
| 34633087 | Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. | Prostate | 2022 |
| 34176768 | Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. | Eur Urol Oncol | 2022 |
| 34038039 | Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. | BJU Int | 2022 |
| 34226663 | A transcriptomic model for homologous recombination deficiency in prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 31047904 | Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database. | Eur Urol Focus | 2021 |
| 33742974 | Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT). | Curr Opin Urol | 2021 |
| 33713162 | Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. | World J Urol | 2021 |